Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALDEROL vs DELTALIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.
Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.
Osteoporosis,Vitamin D deficiency,Renal osteodystrophy,Hypoparathyroidism
Adjunctive treatment of hypocalcemia in hypoparathyroidism,Treatment of refractory rickets,Dietary supplementation for vitamin D deficiency
Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.
0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.
Terminal elimination half-life is approximately 20-30 hours; clinically, steady-state is achieved within 5-7 days.
Terminal elimination half-life ranges from 24 to 36 hours in adults with normal renal function; may be prolonged (up to 72 hours) in renal impairment.
Hydroxylated in liver to 25-hydroxyvitamin D; further hydroxylated in kidney to active 1,25-dihydroxyvitamin D.
Hepatic hydroxylation to active metabolites (e.g., calcifediol, calcitriol); undergoes enterohepatic recycling.
Primarily fecal (biliary) as unchanged drug and metabolites (approx. 80%); renal excretion accounts for less than 20%.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose; biliary/fecal elimination accounts for 30-40%, primarily as metabolites.
Approximately 99% bound to serum proteins, primarily to vitamin D-binding protein (DBP) and albumin.
~95% bound primarily to albumin and alpha-1-acid glycoprotein.
Vd is approximately 0.4 L/kg; reflects distribution into total body water with negligible storage in fat.
Apparent volume of distribution (Vd) is 0.5-1.0 L/kg, indicating moderate tissue distribution.
Oral bioavailability of calcitriol is approximately 70-90%.
Oral: 80-90%; Intramuscular: 90-100% (assumes complete absorption); Intravenous: 100%.
e GFR <30 m L/min/1.73m2: reduce dose by 50% and monitor calcium/phosphate levels; e GFR <15 m L/min/1.73m2: avoid use due to risk of hypercalcemia.
No adjustment required for GFR ≥30 m L/min; use with caution and reduce dose by 50% for GFR <30 m L/min; contraindicated in dialysis.
Child-Pugh class B or C: reduce initial dose by 50% and titrate slowly; monitor calcium and albumin levels.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
For hypocalcemia: 0.05-0.1 mcg/kg/day PO, titrated in 0.05 mcg/kg increments every 2-4 weeks; not recommended for IV use in neonates.
0.01 mg/kg orally once daily, not to exceed 0.5 mg daily; adjust based on response.
Start at the lowest adult dose (0.25 mcg PO daily); increase cautiously due to reduced renal function; monitor serum calcium and renal function frequently.
Initiate at 0.25 mg orally once daily; titrate slowly due to increased sensitivity and risk of hypotension.
None
None.
Hypercalcemia,Hypercalciuria,Renal impairment,Monitoring of serum calcium and phosphorus required
May cause hypercalcemia; monitor serum calcium and phosphate levels regularly. Use with caution in patients with renal impairment, hyperphosphatemia, or sarcoidosis. Avoid use in patients with evidence of vitamin D toxicity.
Hypercalcemia,Vitamin D toxicity,Malabsorption syndrome,Severe renal impairment
Hypercalcemia, hypervitaminosis D, malabsorption syndrome, and known hypersensitivity to vitamin D or any component of the formulation.
Avoid high-calcium foods or supplements unless directed. Vitamin D analogs may alter calcium absorption. No specific food restriction.
No specific food interactions; however, dietary calcium intake should be consistent. High magnesium foods may affect absorption? No. Avoid excessive intake of calcium-rich foods if hypercalcemia risk.
FDA Pregnancy Category C. First trimester: Potential for cardiac malformations (case reports). Second/third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and pulmonary hypertension. Avoid use after 20 weeks gestation.
FDA Pregnancy Category D. Vitamin D analogues can cause hypercalcemia, which may lead to fetal supravalvular aortic stenosis, elfin facies, and intellectual disability. Risk is highest in the first trimester. Avoid use during pregnancy unless benefit outweighs risk.
Excreted in breast milk; M/P ratio unknown. Potential for adverse vascular effects in infants. Contraindicated in breastfeeding due to risk of ductus arteriosus constriction.
Deltalin is excreted in human milk. The M/P ratio is unknown. Caution is advised; consider the risk of hypercalcemia in the breastfed infant. Monitoring of infant serum calcium is recommended if used.
No standard dose adjustment. Use lowest effective dose for shortest duration. Contraindicated after 20 weeks gestation; avoid in first trimester if possible due to teratogenic potential.
Dose adjustments may be necessary due to increased vitamin D metabolism and clearance during pregnancy. Monitor serum calcium and 25-hydroxyvitamin D to guide dosing. Initial doses may require increase, but avoid supratherapeutic levels.
Calderol (calcifediol) is a vitamin D analog used for renal osteodystrophy. Monitor serum calcium and phosphate levels; do not use with severe hypercalcemia or vitamin D toxicity. Dose adjustment needed in dialysis patients.
Deltalin (ergocalciferol) is a vitamin D2 supplement used for deficiency and prophylaxis. Monitor serum calcium and phosphate levels during therapy. Use caution in patients with hypercalcemia, hypercalciuria, or renal impairment. Deltalin can increase digoxin toxicity risk via hypercalcemia. For rickets, radiographic healing confirms efficacy.
Take exactly as prescribed; do not take extra doses.,Avoid calcium supplements and antacids without consulting your doctor.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, weakness, confusion.,Not for use in children.,Store at room temperature away from light and moisture.
Take exactly as prescribed; do not double dose if missed.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, weakness, or confusion.,Avoid taking with other vitamin D supplements unless directed by healthcare provider.,Inform healthcare provider of all medications, especially digoxin, thiazide diuretics, and antacids.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALDEROL vs DELTALIN, answered by our medical review team.
CALDEROL is a Vitamin D Analog that works by Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.. DELTALIN is a Vitamin D Analog that works by Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALDEROL and DELTALIN depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALDEROL is: Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.. The standard adult dose of DELTALIN is: 0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALDEROL and DELTALIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALDEROL is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for cardiac malformations (case reports). Second/third trimester: Risk of premature closure of ductus arteriosus, oligohydramni. DELTALIN is classified as Category C. FDA Pregnancy Category D. Vitamin D analogues can cause hypercalcemia, which may lead to fetal supravalvular aortic stenosis, elfin facies, and intellectual disability. Risk is hig. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.